NCT00449410

Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients

Silent Cerebrovascular Lesion and Cognitive Decline Prevention in Atrial Fibrillation by Intensive Cholesterol Lowering in Elderly Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 35 (planned)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 68 Years – 82 Years
• Healthy volunteers: Not accepted

Summary

In elderly patients with atrial fibrillation (AF) the presence of silent brain infarcts and neurocognitive deficit is high despite adequate treatment with oral anticoagulation. Atherosclerosis is considered to be a chronic inflammatory disease and thrombosis and inflammation are strongly correlated. Atrial fibrillation is linked with increased levels of inflammatory markers and intensive cholesterol lowering has proven to reduce inflammation. In a prospective double-blind randomized pilot-study we want to test the hypothesis, that addition of intensive cholesterol lowering treatment besides adequate oral anticoagulation will reduce cerebrovascular lesions and will be beneficial for neurocognitive status in elderly AF patients.

Conditions

• Atrial Fibrillation
• Neuropsychology
• Magnetic Resonance Imaging
• Inflammation
• Hemostasis

Interventions

Type	Name	Description
DRUG	Atorvastatin
DRUG	ezetimibe

Timeline

• Start date: 2005-05-01
• Completion: 2006-10-01
• First posted: 2007-03-20
• Last updated: 2007-03-20

Locations

1 site across 1 country: Netherlands